At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play.

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

In May of that year, a team at the University of California, Berkeley, filed its first patent application in the U.S. for CRISPR-Cas9. In December, a different team at the Broad Institute of MIT ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in ... a precise method for genetic modification in Streptococcus pneumoniae that enables high-throughput and scalable ...

The CRISPR specialist said that a single 50mg infusion of NTLA-2002 – which switches off a gene involved in the potentially life-threatening inflammatory attacks that characterise HAE ...

The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer Doudna – said it is focusing on NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex ...